Greg Angstreich, MD

Dr. Angstreich completed a Medical Oncology and Hematology Fellowship at the Johns Hopkins Hospital Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, from 2001-2004. His formal medical training began with the Traditional Internal Medicine Internship and Residency Program at Barnes-Jewish Hospital in St. Louis, Missouri, from 1997-2000.

Additionally, he graduated with College Honors from Washington University in 1993 and with a Letter of Commendation from Washington University School of Medicine in 1997, both in St. Louis, Missouri.
Dr. Angstreich is a member of the American Society of Clinical Oncology and the American Society of Hematology. He is also Board Certified in Internal Medicine, Hematology and Medical Oncology and has vast experience treating all malignancies, as well as all benign and cancerous blood disorders.

• Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors Br J Haematol. 2005 Aug; 130(3):373-81. . View in PubMed
• Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant Curr Opin Oncol. 2004 Mar; 16(2):95-9. . View in PubMed

• Kloner, Robert
• Eisenberg, Burton
• Lenz, Heinz-Josef
• Agulnik, Mark